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Abstract
Initial results from sequencing studies suggest that there are relatively few low-frequency (<5%) variants associated with large
effects on common phenotypes. We performed low-pass whole-genome sequencing in 680 individuals from the InCHIANTI
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study to test twoprimaryhypotheses: (i) that sequencingwould detect single low-frequency–large effect variants that explained
similar amounts of phenotypic variance as single common variants, and (ii) that some common variant associations could be
explained by low-frequency variants. We tested two sets of disease-related common phenotypes for which we had statistical
power to detect large numbers of common variant–common phenotype associations—11 132 cis-gene expression traits in 450
individuals and 93 circulating biomarkers in all 680 individuals. From a total of 11 657 229 high-quality variants of which
6 129 221 and 5 528 008were common and low frequency (<5%), respectively, low frequency–large effect associations comprised
7% of detectable cis-gene expression traits [89 of 1314 cis-eQTLs at P < 1 × 10−06 (false discovery rate ∼5%)] and one of eight
biomarker associations at P < 8 × 10−10. Very few (30 of 1232; 2%) common variant associations were fully explained by low-
frequency variants. Our data show that whole-genome sequencing can identify low-frequency variants undetected by
genotyping based approaches when sample sizes are sufﬁciently large to detect substantial numbers of common variant
associations, and that common variant associations are rarely explained by single low-frequency variants of large effect.
Introduction
Initial results from sequencing studies suggest that there are
relatively few low-frequency (minor allele frequency <5%) var-
iants associated with large effects on common human pheno-
types (1–5). However, few of these sequencing experiments
have used sample sizes similar to those required to identify
most common variant–phenotype associations (1,4). Still fewer
sequencing studies have examined the whole genome, instead
most have focused on exomes (5) or targeted sets of genes (1,6)
or have focused on population genetics rather than phenotype
associations (7). Given that the proportion of phenotype variance
explained is a function of allele frequency and effect size [ap-
proximated as β2 × (2pq)], limitations in sample size mean that
many current sequencing studies are powered to detect only
those single low-frequency variants that explain substantially
more phenotypic variance than single common SNPs. In this
study, we deﬁne ‘low frequency–large effect’ as a variant that
has a minor allele frequency <5% but that has a sufﬁciently
large per-allele effect on a phenotype that it explains a similar
proportion of phenotypic variance as common variants detect-
able in the same sample size.
Current whole-genome and exome sequencing-based studies
are aiming to answer several questions of relevance to common
disease and quantitative phenotypes. First, how many low fre-
quency and rare variant associations can we reasonably expect
to identify and in what sample sizes? Second, are common vari-
ant–common phenotype associations driven by low frequency
associations? Third, could we do just as well by imputing geno-
types from the 1000 Genomes Project and other reference panels?
These questions are important for a number of reasons. First, it is
known that most human genetic variation is low frequency and
rare but there is considerable debate as to how best to identify
which of these variants are associated with common pheno-
types. Studies include whole-exome and gene-targeted
approaches (5,6) low-pass sequencing in unrelated individuals
(4) and high-pass sequencing in families. Second, if low fre-
quency and rare variants are responsible formany common vari-
ant–common phenotype associations it will likely implicate a
different set of causal genes and regulatory elements for follow
up. Finally, few studies have tested the power of imputation
from reference panels to identify low-frequency association sig-
nals and this approach could be the most efﬁcient way of study-
ing lower frequency effects in large sample sizes, as recently
shown by a deCODE study (8).
To help answer these questions we performed low-pass
(median 7×) whole-genome sequencing in 680 individuals from
the population based InCHIANTI study (Table 1; Supplementary
Material, Fig. S1 and Table S1; Materials and Methods). We se-
lected two sets of common phenotypes for which the InCHIANTI
study provided sufﬁcient statistical power to detect large num-
bers of common variant–common phenotype associations—
11 132 whole-blood based cis-gene expression traits in 450
individuals, and 93 circulating biomarkers in 673 individuals. Pre-
vious microarray based GWAS of 1200 InCHIANTI individuals
detected 1298 cis-eQTLs and 30 circulating biomarker associa-
tions (9,10). In addition to providing good power to detect com-
mon variant associations, these phenotypes are highly relevant
to human disease. Multiple studies have shown that common
variant disease associations are enriched for variants affecting
gene expression in cis and trans (11–16) and our biomarkers in-
cluded many of public health importance: vitamins A and D;
cholesterol;magnesium, calciumandpotassium ions; inﬂamma-
tory markers and circulating proteins associated with metabolic
disease (including leptin and adiponectin).
We tested two main hypotheses. First, that whole-genome
sequencing would detect single low-frequency genetic variants
that individually explain a similar proportion of phenotypic vari-
ance as single common genetic variants. Our second main
hypothesis was that some individual common variant–common
phenotype associations would be explained by low frequency
variants. As a secondary hypothesis that has recently been tested
in other studies (7), we also tested whether or not low frequency
variant–common phenotype associations would be better cap-
tured by low-pass sequencing than imputation from the 1000
Genomes Project.
Results
Analysis of our median 7-fold whole-genome sequencing data
detected 11 657 229 high-quality variants (10 144 717 SNPs and 1
512 512 indels) (see Materials and Methods for deﬁnition of high
quality) and had aminor allele count (MAC)≥ 4. Of these variants
6 129 221, 5 528 008 and 2 917 071 had a minor allele frequency
(MAF) ≥5% (common), MAF <5% (low frequency) and MAF <1%
but MAC ≥ 4, respectively. We limited tests to those with a MAC
Table 1. Basic characteristics of the 680 InCHIANTI individuals
selected for sequencing at baseline
Characteristic Mean (range) or %
Age (years) 64.2 (23–90)
Sex (% male) 44.9%
Body mass index 27.2 (18.1–46.6)
Current smokers (% case) 21.3%
History of hypertension (% case) 33.8%
History of diabetes (% case) 8.7%
History of myocardial infarction (% case) 2.6%
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≥4 because we had limited power to detect associations with
three or less alleles. A full break down of the numbers of variants
tested for each of the analyses is shown in Table 2, Figure 1 and
Supplementary Material, Tables S2 and 3.
A number of analyses provided strong evidence that our data
were of high quality (Materials and Methods; Supplementary
Material, Figs. S2–5 and Tables S4–7). We compared genotypes
generated by low-pass sequencing with those identiﬁed from a
separate targeted deep-sequencing (128×) experiment of 2 Mb
of (non-contiguous) sequence from 83 overlapping individuals.
This comparison provided an estimate that 99.4% of the variants
identiﬁed by low-pass sequencing were true positives and a false
negative (variants missed by low-pass sequencing but detected
in deep-sequence data) rate of 11.9%. Equivalent ﬁgures for indels
were in keepingwith the increased difﬁculty of scoring these var-
iants from low-pass sequencing data at 84 and 20.7%, respective-
ly (Materials and Methods; Supplementary Material, Fig. S3 and
Tables S4–7). Finally, a comparison between non-reference SNP
genotypes generated by low-pass sequencing and GWAS chip
data provided strong evidence that genotypes of common var-
iants were accurately (mean genotype concordance of 99.7%)
genotyped (Materials and Methods; Supplementary Material,
Figs. S4 and 5).
All gene expression and biomarker phenotypes were inverse-
normalized. A list of the 93 circulating biomarkers can be found in
the Supplementary Material, Table S8. To assess the number of
independent variants and tests wewere performing, we random-
ly selected a 2 Mb region from each of the 22 chromosomes and
used LDselect (17) and an r2 cut off of 0.8 to deﬁne independent
signals (a likely conservative cut-off ) (Materials and Methods;
and SupplementaryMaterial, Table S9).We conditioned all single
common variant–phenotype associations on the most strongly
associated single low-frequency variants within the locus (1 Mb
either side), and vice versa conditioned all low frequency–
phenotype associations on more strongly associated common
variants in the same region (Materials and Methods). We used
several approaches to test the robustness of our associations in-
cluding testing cis-eQTL associations in a replication study—gene
expression and high-pass (60×) whole-genome sequence data
from 643 individuals from the San Antonio Family Heart Study
(SAFHS) (Materials and Methods)—and validation of a subset of
11 low frequency variants with bespoke genotyping (Materials
and Methods).
We identiﬁed 1314 cis-eQTLs at P < 1 × 10−06 and 8 biomarker
associations at P < 8 × 10−10, and for cis-eQTLs observed a continu-
ous distribution between lower frequency variants of larger effect
and higher frequency variants of smaller effect (Fig. 2 and Sup-
plementary Material, Tables S10 and 11). Of the 6 129 221 com-
mon (>5%) and 5 528 008 low-frequency variants tested we
identiﬁed 0.02 and 0.002%, respectively, as cis-eQTLs at P < 1 ×
10−06. Low frequency–large effect associations comprised 7% of
detectable cis-gene expression traits (89 of 1314) and one of
eight biomarker associations. The average effect size of low fre-
quency index variants was 1.36 (range 0.80–2.39) standard devia-
tions and the average effect size of common index variants was
0.61 (range 0.32–1.73) standard deviations (Supplementary
Table 2. A breakdown of the number of variants with minor allele count ≥4 tested in the cis-eQTL and circulating biomarker analyses
Analysis All Variants MAF < 0.05 MAF≥ 0.05
N variants
tested
N estimated
independent
N variants
tested
N estimated
independent
N variants
tested
N estimated
independent
cis-eQTLs 9 187 579 3 480 256 3 760 279 2 547 870 5 427 300 950 716
Biomarkers 11 657 229 4 272 000 5 528 008 3 127 500 6 129 221 1 167 000
Details of how we estimated the number of independent variants can be found in Materials and Methods.
Figure 1. The total number of variants (low frequency and common) tested in the cis-eQTL and circulating biomarker analyses.
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Material, Tables S10 and S11). These differences in per-allele ef-
fect size were expected given that lower frequency variants
need to have larger per-allele effects to be detected (see Table 3
for power calculations).
Our low-pass sequencing approach meant that we were able
to accurately capture and analyze a similar number of low-
frequency variants (5 528 008, including 2 917 071 at allele frequency
<1%) as common variants (6 129 221). However, proportional to
the number of variants analyzed, we detected far fewer low-
frequency variant associations than common variant associa-
tions despite the same statistical power to detect individual
variants explaining the same proportion of phenotypic variance.
In Table 3 we show how statistical power remains ﬁxed for var-
iants explaining similar proportions of phenotypic variance,
but how standard deviation effect sizes need to be higher for
lower frequency variants. In total, we identiﬁed 89 low-frequency
cis-eQTLs and 1 low frequency–circulating biomarker association
comparedwith 1225 common cis-eQTLs and 7 common biomark-
er associations (Supplementary Material, Tables S10 and 11).
Accounting for linkage disequilibriumbetween variants accentu-
ated this difference—for cis-eQTLs the low-frequency variant
associations represented 0.003% of an estimated 2 547 870 in-
dependent low-frequency variants (where independence was
deﬁned as r2 < 0.8), while the common variant associations repre-
sented 0.12% of an estimated 950 716 independent common var-
iants (r2 < 0.8) (Table 2 and Fig. 1). These comparisons were not
inﬂuenced by differences in quality of genotypes between low
frequency and common variants becausewe only compared var-
iants of high quality. Under an alternative genetic architecture,
we could have expected to identify 1105 low-frequency variants
associated with cis-gene expression (0.02% of 5 528 008 low-fre-
quency variants tested—the same proportion of common var-
iants associated with gene expression), given we had the same
statistical power to detect single low frequency–large effect var-
iants that explain a similar proportion of phenotypic variance
as single common smaller effect variants. Instead our data are
consistent with the argument that only a small proportion of
single low-frequency variants will have large enough per-allele
effects to explain a similar proportion of phenotype variance as
single common variants. Our data do not rule out the possibility
that many 1000s of low-frequency variants of moderate and
small effect could collectively account for more phenotype
variance than common variants collectively.
Analyses of gene expression phenotypes in a second dataset
suggested that the associations observed were robust—of 233
cis-eQTLs associations where the same gene was probed with
the same expression probe sequence in a second study of similar
size (N = 643 related individuals, Materials and Methods), we de-
tected 166 associated at a Bonferroni corrected P-value of <0.0002
and 222 of 236 were directionally consistent. Of these 12 of 17
testable low-frequency associations reached P < 0.0002 and all
17were directionally consistent. For example, low-frequency var-
iants in or near the genes ACAD9, HDHD3, SOS1, UTS2, RTN1 and
RBPMS2 inﬂuenced the expression of those genes with per-allele
effects of >1 standard deviation in the replication data, where
winner’s curse would not have appreciably inﬂuenced the effect
size. No data were available to replicate the single low-frequency
variant associated with a biomarker. This biomarker was lactate
dehydrogenase and we could not identify any studies with rele-
vant measures (Supplementary Material, Table S12).
We next assessed the extent to which common variant asso-
ciations were driven by low-frequency associations, and vice
versa, by conditioning on the most strongly associated variants
in the alternative allele frequency bin. All evidence of association
Figure 2. The distribution of effect sizes of index cis-eQTL variants by MAF.
Table 3. Statistical power to detect variants associatedwith gene expression in 450 individuals at P = 1 × 10−6 as a function of phenotypic variance
explained and standard deviation (SD) effect size
MAF Variance Power Effect (SD) Variance Power Effect (SD) Variance Power Effect (SD)
0.01 0.05 0.47 1.59 0.06 0.65 1.74 0.07 0.79 1.88
0.02 0.05 0.47 1.13 0.06 0.65 1.24 0.07 0.79 1.34
0.03 0.05 0.47 0.93 0.06 0.65 1.02 0.07 0.79 1.10
0.04 0.05 0.47 0.81 0.06 0.65 0.88 0.07 0.79 0.95
0.05 0.05 0.47 0.73 0.06 0.65 0.79 0.07 0.79 0.86
0.1 0.05 0.47 0.53 0.06 0.65 0.58 0.07 0.79 0.62
0.2 0.05 0.47 0.40 0.06 0.65 0.43 0.07 0.79 0.47
0.01 0.08 0.89 2.01 0.09 0.95 2.13 0.10 0.98 2.25
0.02 0.08 0.89 1.43 0.09 0.95 1.52 0.10 0.98 1.60
0.03 0.08 0.89 1.17 0.09 0.95 1.24 0.10 0.98 1.31
0.04 0.08 0.89 1.02 0.09 0.95 1.08 0.10 0.98 1.14
0.05 0.08 0.89 0.92 0.09 0.95 0.97 0.10 0.98 1.03
0.1 0.08 0.89 0.67 0.09 0.95 0.71 0.10 0.98 0.75
0.2 0.08 0.89 0.50 0.09 0.95 0.53 0.10 0.98 0.56
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was lost (P > 0.05) for 13 of 1232 common variant associations
when conditioning on the strongest low frequency variant and
969 of 1232 remained associated with our statistical thresholds.
We next repeated the analyses but conditioned all common vari-
ant associations on all independent (r2 < 0.2) low-frequency var-
iants reaching P < 1 × 10−04 in the cis region of the expression
probe orwithin 1 Mbof the common index variants for biomarker
associations. All evidence of association was lost (P > 0.05) for 30
of the 661 (5%) common signals that had at least one low-
frequency association at the same locus. These results strongly
suggested that few of the common associations were driven by
single or multiple low-frequency variants. For low-frequency
variants, all evidence of association was lost (P > 0.05) for 11 of
90 associations and 47 of the 90 remained associated at our
thresholds when adjusting for the strongest common variant in
the region (46 of the 89 low frequency cis-eQTL signals and 1 of
1 low-frequencybiomarkerassociations) (SupplementaryMaterial,
Tables S13 and 14).
The availability of 1000 Genomes reference sequence has
improved the ability to accurately capture low-frequency var-
iants andmaymean that low-pass sequencing individual studies
is an inefﬁcient use of research funds. We therefore next as-
sessed how well low-frequency variant associations would
have been detected without any sequence data from the In-
CHIANTI study but by using data from the 1000 Genomes Project
as a reference panel for imputation and the GWAS array (Illumina
HumanHap550K) genotypes as a scaffold.Weused an imputation
reference panel comprised of 2184 haplotypes from 1092 indivi-
duals sequenced and phased by the 1000 Genomes Project. Of
these, 379 individuals were of European descent and included
98 individuals from Tuscany (the same part of Italy as the In-
CHIANTI study). Of the 90 low-frequency signals (89 cis-eQTLs,
1 biomarker), detected by sequencing, we did not detect 63%
(57) based on the same statistical thresholds using 1000 Genomes
imputation alone (all cis-eQTLs) (Supplementary Material, Tables
S15 and 16). Ignoring statistical thresholds, 85% of all cis-eQTL
and biomarker associations identiﬁed through sequence-based
analysis were less strongly associated in the 1000 Genomes im-
puted dataset or had no proxy within 250 Kb of the index variant
(Supplementary Material, Tables S15 and 16). However, 62 (69%)
of the 90 low-frequency variant associations were detected at
P < 0.0001, illustrating that imputation from the 1000 Genomes
reference panel captures most of the low-frequency variants,
just not as accurately.
Discussion
Our study provides an early example of awhole-genome sequen-
cing experiment designed to identify low-frequency variants
associated with common human phenotypes. We could accept
our ﬁrst main hypothesis. We show that, when using the same
sample size for detecting both common and low frequency var-
iants, whole-genome sequencing has the ability to identify low
frequency variants with larger effect sizes (and similar pheno-
typic variance explained) than those observed for common
variants. However, our data suggest that these single-variant
low-frequency large effect signals may represent a relatively
small proportion (here 7%) of detectable associations. Our data
are consistent with the majority of single low-frequency genetic
variants explaining smaller proportions of phenotypic variance
than single common genetic variants. This result was perhaps
expected, but given our sequencing-based approach allowed us
to test a similar number of high-quality low-frequency variants
(5 528 008) as common variants (6 129 221) we could reasonably
have expected to identify ∼1105 low-frequency cis-eQTLs under
a different genetic architecture. If extrapolated to other common
human phenotypes, our results would indicate that, for example,
whole-genome sequenced (or perhaps extremely well imputed)
sample sizes of 35 000 cases and equivalent controls will be
needed to detect ∼5 single low-frequency variants associated
with type 2 diabetes (7% of 65, ref. 18). These are obviously very
cautious extrapolations because the genetic architecture of cis-
gene expression and circulating biomarkersmay be very different
compared with other phenotypes. Nevertheless, there is strong
evidence that changes to cis-gene expression is a commonmech-
anism leading to common disease and quantitative phenotypes
(11–16) and a recent whole-genome sequence and imputation-
based study provides evidence that these estimates may be of
the correct order of magnitude—an effective sample size of
13 500 type 2 diabetes cases detected ﬁve low frequency (MAF <
5%) large effect type 2 diabetes associations (8).
Our data enabled us to largely reject our second main
hypothesis—that common variant–common phenotype associa-
tions are explained by individual or multiple low-frequency var-
iants. Only 30 (2%) common variant associations were driven by
low frequency (and by necessity larger effect) variants. In con-
trast, a larger fraction (12%) of low-frequency variantswas entire-
ly driven by common variant associations at the same locus. We
also note that, as with most sequencing studies, low-frequency
insertion/deletion variants were harder to call and we may
have missed true associations caused by these types of variant.
Of note, 13% (12) of the 90 low frequency–large effect and 11%
(137) of the 1232 common variant association signals included
an indel as the most strongly associated variant.
In keeping with other recent studies we were able to accept
our secondary hypothesis. Our data clearly show that whole-
genome sequencing is more effective than imputation from the
current 1000 Genomes Project reference panel. Imputation of
missing genotypes missed 63% of low frequency–large effect
associations detected by whole-genome sequencing at P < 1 ×
10−6, and 31% at P < 1 × 10−4. Nevertheless, larger reference panels
will improve the ability of imputation to capture low-frequency
variants and it is notable that 1000 Genomes imputation cap-
tured at least half the genotype information (r2 > 0.52) for 75%
of the low frequency signals. As noted by other studies (7),
these ﬁndings emphasize the need for larger reference panels
from which to impute missing genotypes into extremely large
GWAS datasets.
There were a number of limitations to our study. First, our
conclusions are based largely on testing 1000s of cis-gene expres-
sion phenotypes rather than thewhole genome for a small num-
ber of phenotypes. However, the costs of whole-genome
sequencing have so far limited single study sample sizes to
<3000 samples, and our approach had the advantage that we
were well powered to detect many common variant–common
phenotype associations. This advantage meant we were able to
make a fair comparison between common and low-frequency
variants. Our data may also be relevant to disease phenotypes
because numerous studies have shown that many disease
associations are enriched for cis-gene expression effects
(11–16). A second limitation is that we did not assess more
detailed phenotypes or genotype combinations. For example, a
recent study has shown that low-frequency variants may be a
frequent cause of allele and exon-speciﬁc changes to gene ex-
pression (19). Furthermore we could not test the role of most
rare variants (<0.5%) in our study because our sample size lim-
ited analyses to those occurring at 0.3% frequency or more
(minor allele count ≥4). However, our approach meant we were
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able to analyze 2.9 million accurately called variants with allele
frequencies of <1%.
In conclusion, our approach provided an unbiased assess-
ment of the relative contribution of low frequency and common
genetic variation to common quantitative phenotypes of rele-
vance to human disease. Our study shows that low-pass whole-
genome sequencing can identify low frequency–large effect
variants in common human phenotypes using sample sizes suf-
ﬁciently large to provide statistical power to detect large numbers
of common variant associations.
Materials and Methods
Samples
We selected 680 individuals from the InCHIANTI study (9,20); a
study of aging from the Chianti region in Tuscany, Italy, for
low-pass whole-genome sequencing (Table 1). Selection criteria
included the availability of microarray genotype data and non-
missingness of phenotypic data that included gene expression
data and circulating biomarker.
Whole-genome sequencing
Whole-genome sequencing was performed at the Beijing Gen-
omics Institute (BGI), Shenzhen, China using Illumina HiSeq
2000 to obtain a minimum read depth of 6× and median of 7×.
An average of 240 million paired-end 90 bp reads per sample
were aligned to the 1000 Genomes implementation of the build
37 genome reference consortium human reference genome (21),
using the burrows-wheeler aligner (BWA) version 1.5.9 (22)
(Supplementary Material, Fig. S1 and Table S1).
Sequence read processing
Using the sequence reads aligned at BGI through BWA, each gen-
ome was scanned for small insertions and deletions (indels)
using the Genome Analysis Toolkit (GATK) version 1.6 indel re-
aligner (23). This process detected both de novo and known
indels from dbSNP version 135 (24). Regions containing indels
were then realigned to the reference genome. Duplicated reads
across the genomewere detected using Picard version 1.59 (avail-
able from http://picard.sourceforge.net) and subsequently re-
moved to avoid potential bias when genotyping. In addition,
base quality scores in each aligned read were recalibrated using
the GATK version 1.6 table recalibrator. Recalibration used read
group, reported quality score, sequencing machine cycle and se-
quence context as covariates.
Sequence variant identiﬁcation
SNP and indel calling was performed across all 680 genomes
using the GATK version 2.2 uniﬁed genotyper. False-positive vari-
ant calls were ﬁltered using variant quality score recalibration
(VQSR). VQSR developed a covarying estimate of the relationship
between eight variant call annotations (read depth, mapping
quality, quality of read depth, haplotype score, inbreeding coefﬁ-
cient, mapping quality bias, strand bias and read position bias)
and the probability that the call is a true genetic variant. The
truth model was determined adaptively based on HapMap 3.3
sites and polymorphic sites from the 1000 genomes Omni 2.5 M
SNP chip array (25,26).
Quality control of variant capture and sequence-based
genotype calls
As a quality control check we ﬁrst used GATK’s variant annotator
(version 2.2) to determine the overlap of discovered variants cat-
aloged in HapMap 3.3 (26), 1000 Genomes Omni 2.5 and the 1000
Genomes phase 1 indel dataset (25) (Supplementary Material,
Fig. S2).
Imputation of sequence data to recover and reﬁne
genotype sites
Haplotype phasing was performed using Beagle version 3.3 (27),
and missing data were imputed internally using the ﬁltered
and present genotypes only. For SNPs we observed an overall
Ti/Tv of 2.19. A summary of the variants captured can be found
in the Supplementary Material, Tables S2 and S3.
Variant and genotype comparison with 2 Mb
of high depth sequence (median >30×)
Wecompared variants captured though our low-pass sequencing
experiment with regions known to associated with Parkinson’s
disease sequenced at high depth (median >30×) in 96 InCHIANTI
subjects (total of ∼2 Mb). SNP and indel calling was performed
across the 96 samples using the GATK’s uniﬁed genotyper (ver-
sion 2.2). SNPs were ﬁltered using VQSR and indels were hard ﬁl-
tered using GATK version 2.2 variant ﬁltration. Of the 96 subjects,
83 subjects overlapped formed a subset of the 680whole-genome
sequenced subjects.
To assess the quality of the variants captured and the geno-
types called in low-pass sequencing we created a high quality
set of variants and genotypes called in the high depth 2 Mb of
sequence data. We ﬁltered by (1) masking out polymorphic re-
gions in chromosome 6 and 17 in the 2 Mb regions in both data-
sets; (2) removing sites containing a genotype called at <20×
coverage in the high-depth sequence dataset from both datasets;
(3) removed all non-biallelic sites from the respective dataset.
The degree of overlap was then calculated each way for both
of the ﬁltered 2 Mb datasets using the GATK version 2.2 variant
annotator and the genotype concordance matrices were calcu-
lated in overlapping sites using VCFtools version 0.1.9 (28)
(Supplementary Material, Fig. S3 and Tables S4–7).
Quality control of genotypes derived from
sequence-based imputation
As an additional quality control check of internally imputation
genotypes we performed genotype concordance checks with
the Illumina HumanHap550 GWAS chip. Of the 680 subjects,
7 were selected for exclusion as the fraction of concordant geno-
types for each subject was consistent with a sample swap (52%
concordance in each instance). For the remaining 673 subjects
we observed good concordance with the genotyping array
(>98% concordance). For all 673 samples genotyping calls in-
creased after internal imputation performed by Beagle (Supple-
mentary Material, Figs. S4 and 5).
1000 Genomes imputation
To compare whole-genome sequencing to imputation from the
1000 genomes reference panel we used haplotypes from the
1000 Genomes Phase I integrated (version 3) release with single-
tons removed (30 061 896 variants; 28 681 763 SNPs and 1 380 133
indels). Genotype data captured on the Illumina HumanHap550
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chip were phased using MACH 1.0.16 (29,30). Subsequent imput-
ation was performed using Minimac (version 2012.10.9) (31). We
used a multi-ethnic haplotype reference panel that included
1092 individuals including 379 Europeans (including 98 Tuscans),
181 Americans, 246 Africans and 289 Asians, in an attempt to
capture variants that may be rare in Europeans but more com-
mon on haplotypes from different ethnic backgrounds.
Variants included in association analyses
For all association analyses we ﬁltered on biallelic variants with a
minor allele count ≥4 and an r2 imputation quality >0.7. To en-
sure comparable imputation metrics between the Beagle- and
MaCH/Minimac-derived dosages we recalibrated the Beagle im-
putation metric to MaCH’s r2 (30). As described above, Beagle
was used to reﬁne and recover genotypes for the variant sites
identiﬁed by the low-pass sequencing data.
cis-eQTL association analysis
Whole-genome expression proﬁles of the InCHIANTI subjects
were derived from whole blood and captured using the Illumina
HT12-v3 BeadChip as previously described (32). We excluded
probes that harbored non-singleton variants within the 50 bp
probe region captured by our sequencing efforts or the Exome
Sequencing Project (33). This resulted in 11 132 probes for associ-
ation testing.We performed kinship analysis using KING (34) and
removed ﬁrst-degree relatives from the analysis that resulted in
450 remaining individuals. We inverse-normalized the intensity
values for the ﬁltered probes and individuals prior to generating
residuals that adjusted for age, sex, ampliﬁcation batch and
hybridization batch to increase the likelihood of the error around
the model being normally distributed. Finally, we inverse-
normalized the residual values prior to performing the associ-
ation analyses. We performed association testing in cis having
deﬁned a cis region as ±1 Mb the probe transcription start site. Do-
sages output by BEAGLE were formatted for MACH2QTL (29,30)
and variants in cis tested against the normalized intensity values
of the respective probe.
Circulating biomarker association analyses
A full list of the 93 circulating biomarkers is provided in the Sup-
plementary Material, Table S8. For the 93 circulating biomarkers
we similarly performed a double inverse-normalization for each
trait but inversed normalized the raw data values, and adjusted
for age and sex only when generating the residuals. We tested
the entire genome for associations against each of the circulating
biomarkers using all 673 chip-concordant subjects. We used a
mixed-linear model as implemented in EMMAX (35) to account
for relatedness instead of removing subjects from the analysis.
Estimating numbers of independent variants
using 2 Mb windows
We used LDSelect version 1.0 (17) across 22 2 Mb windows (one
per autosomal chromosome) to estimate the average number of
independent variants (MAC≥ 4) we would expect to observe, de-
ﬁning variants as independent if their pair-wise r2 cut-off <0.8.
We estimated an average total of 2848 independent variants
within a 2 Mb window (Supplementary Material, Table S9). In
addition, we observed an average of 2085 and 778 low-frequency
and common independent variants, respectively, within a 2 Mb
window. Only those variants with imputation quality >0.7 were
included in this analysis. Using this information, we estimated
the number of independent variants tested in the association
analyses. As 2 Mb represents ∼1/1500 of the genome we extrapo-
lated estimates for the number of independent variants for the
circulating biomarkers (all and split by minor allele frequency
bin) multiplying by 1500.
Calculating statistical thresholds for association analyses
For cis-eQTLs analyses there were a total of 9 187 579 analyzable
variants (MAC≥ 4 and imputation r2 > 0.7) that fell within 11 132
2 Mb windows around each of the gene expression probes.
Given the estimated number of independent variants within a
2 Mb regionwas 2848we calculated 2848 × 11 122 gene expression
phenotypes = 31 675 456 independent tests. A P-value of 1.6 × 10−9
provides a Bonferroni corrected P-value of 0.05 and a P-value of
∼1 × 10−06 provides a false-discovery rate of ∼5% given the num-
ber of cis-eQTLs we identiﬁed at that threshold (1314).
For the 93 circulating biomarkers we ﬁrst estimated the num-
ber of independent variants across the whole genome by multi-
plying the number of independent (r2 < 0.8) variants in a 2 Mb
window, 2848, by the approximate number of 2 Mb windows,
1500 = 4 272 000. We multiplied this number by number of circu-
lating biomarkers we were testing to give a total of 397 296 000
independent tests. A P-value of 8 × 10−10 provides a Bonferroni
corrected P-value of 0.05.
Conditional analysis using variants in opposing minor
allele frequency bins
For associations that reached our statistical thresholds, we condi-
tioned on the dosage of the most signiﬁcant variant from the op-
posing MAF bin (MAF <5 versus MAF ≥ 5%). These variants were
limited to those either within the 2 Mb cis region of the speciﬁc
expression trait or within 1 Mb of the index variant representing
a circulating biomarker association. To ensure that a lack of
change in signiﬁcance of the index variant was not driven by
the best variant from the opposite minor allele frequency bin
belonging to a secondary signal (creating the potential to miss a
partially tagging variant thatmay not have been themost signiﬁ-
cant in the opposing bin), we performed full conditional analysis
on all traits and conditioned the original index variant identiﬁed
on the best variant from the opposing allele frequency bin from
all additional signals that were observed.
To test further whether or not low-frequency variants could
explain common signals, we conditioned common signals on
all independent low frequency variants (r2 < 0.2) with P < 1 × 10−4
within the region. Association-based variant clumping was per-
formed using PLINK (36) to identify the variants required for
this conditional analysis. Of the 1232 common signals, 661 had
≥1 low frequency variant in the region meeting these criteria.
Three hundred and thirty common signals had two or more
low-frequency variants that we conditioned on.
Replication of cis-eQTLs in the SAFHS
Whole-genome expression proﬁling was performed using Illumi-
na Sentrix Human Whole Genome (WG-6) Series I as previously
described (37) and called genotypes and were provided by the
T2D-GENES Consortium. Genotypes were derived either directly
from high-pass (60×) whole-genome sequencing or through fam-
ily-based genotype imputation in the remaining individuals not
sequenced. In an attempt to harmonize the WG-6 chip and the
HT12-v3 chip we limited our replication efforts to a 397 probe
subset of the 1325 whereby the probe sequences matched across
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the two platforms. Levels of expression were detected for 233/397
probes in 643 SAFHS individuals. Association analyses were per-
formed using mixed-linear models as implemented in RareFAM
that adjusts for a kinship matrix when performing association
testing (available online from http://genome.sph.umich.edu/
wiki/FamRvTest). One variant from the SAFHS replication results
was classiﬁed as spurious and removed prior to testing for correl-
ation with the initial cis-eQTL results as it had an effect size of >9
standard deviations of an inverse-normalized distribution of
gene expression levels.
Validation of low-frequency variants with bespoke
genotyping
We selected 10 low-frequency SNPs associated with cis-eQTLs
and 1 low-frequency lactic dehydrogenase variant for genotyping
at LGC Genomics, UK. For 9/11 SNPs we obtained >99% concord-
ance overall. Therewere two thatwere returned asmonomorphic
(both cis-eQTL variants) (Supplementary Material, Table S17).
Supplementary Material
Supplementary Material is available at HMG online.
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